Literature DB >> 23989217

Advantages and clinical applications of natural killer cells in cancer immunotherapy.

Erik Ames1, William J Murphy.   

Abstract

The past decade has witnessed a burgeoning of research and further insight into the biology and clinical applications of natural killer (NK) cells. Once thought to be simple innate cells important only as cytotoxic effector cells, our understanding of NK cells has grown to include memory-like responses, the guidance of adaptive responses, tissue repair, and a delicate paradigm for how NK cells become activated now termed "licensing" or "arming." Although these cells were initially discovered and named for their spontaneous ability to kill tumor cells, manipulating NK cells in therapeutic settings has proved difficult and complex in part due to our emerging understanding of their biology. Therapies involving NK cells may either activate endogenous NK cells or involve transfers of exogenous cells by hematopoietic stem cell transplantation or adoptive cell therapy. Here, we review the basic biology of NK cells, highlighting characteristics which make NK cells particularly useful in cancer therapies. We also explore current treatment strategies that have been used for cancer as well as discuss potential future directions for the field.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23989217      PMCID: PMC3880590          DOI: 10.1007/s00262-013-1469-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  52 in total

Review 1.  Natural killer cell-based immunotherapy in cancer: current insights and future prospects.

Authors:  T Sutlu; E Alici
Journal:  J Intern Med       Date:  2009-08       Impact factor: 8.989

2.  Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.

Authors:  William H D Hallett; Erik Ames; Maite Álvarez; Isabel Barao; Patricia A Taylor; Bruce R Blazar; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

3.  Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Authors:  Junli Yu; Jeffrey M Venstrom; Xiao-Rong Liu; James Pring; Reenat S Hasan; Richard J O'Reilly; Katharine C Hsu
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

4.  KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

Authors:  Jeffrey M Venstrom; Junting Zheng; Nabila Noor; Karen E Danis; Alice W Yeh; Irene Y Cheung; Bo Dupont; Richard J O'Reilly; Nai-Kong V Cheung; Katharine C Hsu
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

5.  NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells.

Authors:  Oren Hershkovitz; Benyamin Rosental; Lior Ann Rosenberg; Martha Erika Navarro-Sanchez; Sergey Jivov; Alon Zilka; Orly Gershoni-Yahalom; Elodie Brient-Litzler; Hugues Bedouelle; Joanna W Ho; Kerry S Campbell; Bracha Rager-Zisman; Philippe Despres; Angel Porgador
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

6.  Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.

Authors:  E Ames; W H D Hallett; W J Murphy
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

7.  NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.

Authors:  Tadepally Lakshmikanth; Shannon Burke; Talib Hassan Ali; Silvia Kimpfler; Francesco Ursini; Loredana Ruggeri; Marusca Capanni; Viktor Umansky; Annette Paschen; Antje Sucker; Daniela Pende; Veronika Groh; Roberto Biassoni; Petter Höglund; Masashi Kato; Kazuko Shibuya; Dirk Schadendorf; Andrea Anichini; Soldano Ferrone; Andrea Velardi; Klas Kärre; Akira Shibuya; Ennio Carbone; Francesco Colucci
Journal:  J Clin Invest       Date:  2009-04-06       Impact factor: 14.808

Review 8.  NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.

Authors:  Karl-Johan Malmberg; Yenan T Bryceson; Mattias Carlsten; Sandra Andersson; Andreas Björklund; Niklas K Björkström; Bettina C Baumann; Cyril Fauriat; Evren Alici; M Sirac Dilber; Hans-Gustaf Ljunggren
Journal:  Cancer Immunol Immunother       Date:  2008-03-04       Impact factor: 6.968

9.  Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method.

Authors:  L Li; L N Liu; S Feller; C Allen; R Shivakumar; J Fratantoni; L A Wolfraim; H Fujisaki; D Campana; N Chopas; S Dzekunov; M Peshwa
Journal:  Cancer Gene Ther       Date:  2009-09-11       Impact factor: 5.987

10.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

Authors:  Maria Berg; Andreas Lundqvist; Philip McCoy; Leigh Samsel; Yong Fan; Abdul Tawab; Richard Childs
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more
  41 in total

Review 1.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

2.  Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.

Authors:  Elizabeth L Siegler; Yu Jeong Kim; Xianhui Chen; Natnaree Siriwon; John Mac; Jennifer A Rohrs; Paul D Bryson; Pin Wang
Journal:  Mol Ther       Date:  2017-08-19       Impact factor: 11.454

3.  Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.

Authors:  Yunlong Qin; Christina Hutson; Xianfu Wu; Jingyao Xu; Darin Carroll
Journal:  Enliven J Stem Cell Res Regen Med       Date:  2016-07-06

Review 4.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies.

Authors:  Gordana Konjević; Ana Vuletić; Katarina Mirjačić Martinović
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

5.  Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells.

Authors:  Erik Ames; Robert J Canter; Steven K Grossenbacher; Stephanie Mac; Rachel C Smith; Arta M Monjazeb; Mingyi Chen; William J Murphy
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

6.  NK cell therapy for end-stage cancerous patient: A case study.

Authors:  Junichi Masuyama; Kamon Chaiyasit; Wanviput Sanphasitvong; Viroj Wiwanitkit
Journal:  South Asian J Cancer       Date:  2014-04

7.  NKG2D Ligands in Cancer Immunotherapy: Target or Not?

Authors:  Jennifer Wu
Journal:  Austin J Clin Immunol       Date:  2014-01-06

8.  Defining Metastatic Cell Latency.

Authors:  Jeffrey W Pollard
Journal:  N Engl J Med       Date:  2016-07-21       Impact factor: 91.245

9.  NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.

Authors:  Erik Ames; Robert J Canter; Steven K Grossenbacher; Stephanie Mac; Mingyi Chen; Rachel C Smith; Takeshi Hagino; Jessica Perez-Cunningham; Gail D Sckisel; Shiro Urayama; Arta M Monjazeb; Ruben C Fragoso; Thomas J Sayers; William J Murphy
Journal:  J Immunol       Date:  2015-09-11       Impact factor: 5.422

Review 10.  Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.

Authors:  Jesus I Luna; Steven K Grossenbacher; William J Murphy; Robert J Canter
Journal:  Expert Opin Biol Ther       Date:  2016-12-23       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.